García Vanesa, García José M, Peña Cristina, Silva Javier, Domínguez Gemma, Lorenzo Yolanda, Diaz Raquel, Espinosa Pablo, de Sola Javier García, Cantos Blanca, Bonilla Félix
Department of Medical Oncology, Hospital Universitario Puerta de Hierro, C/ San Martín de Porres, 4, E-28035 Madrid, Spain.
Cancer Lett. 2008 May 18;263(2):312-20. doi: 10.1016/j.canlet.2008.01.008. Epub 2008 Feb 15.
We studied by real-time PCR cyclin D1 and thymidylate synthase (TS) mRNA in plasma as possible markers of clinical outcome in breast cancer. We observed poor outcome in patients with presence of cyclin D1 mRNA in good-prognosis groups, such as negative vascular invasion. Presence of both markers was associated with non-response to treatment after relapse. In patients treated with tamoxifen, a trend to significant relation between poor outcome and cyclin D1 mRNA was found. Cyclin D1 mRNA in plasma could identify patients with poor overall survival in good-prognosis groups and patients non-responsive to tamoxifen.
